

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AMGN | NASDAQ | USD | Real-time | |
AMGN | BIVA | MXN | Delayed | |
AMGN | Mexico | MXN | Delayed | |
AAMGN | Milan | EUR | Real-time | |
AMGN | TradeGate | EUR | Delayed | |
AMGN | Frankfurt | EUR | Delayed | |
AMGN | Xetra | EUR | Delayed | |
AMGN | Buenos Aires | ARS | Delayed | |
AMGN34 | BM&FBovespa | BRL | Delayed | |
4332 | Hong Kong | HKD | Delayed | |
AMGN | Vienna | EUR | Real-time |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Name | Age | Since | Title |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
R. Sanders Williams | 74 | 2014 | Independent Director |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Ronald D. Sugar | 74 | 2010 | Independent Director |
Greg C. Garland | 66 | 2013 | Independent Director |
Charles M. Holley | 66 | 2017 | Independent Director |
Robert A. Eckert | 69 | 2012 | Lead Independent Director |
Tyler E. Jacks | 62 | 2012 | Independent Director |
Ellen J. Kullman | 67 | 2016 | Independent Director |
S. Omar Ishrak | 67 | 2021 | Independent Director |
Brian J. Druker | 67 | 2018 | Independent Director |
Amy E. Miles | 56 | 2020 | Independent Director |
Wanda M. Austin | 69 | 2017 | Independent Director |
Michael V. Drake | - | 2022 | Independent Director |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
George Georgiou | 64 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review